1

2
Albrecht Brian K, Bellon Steven, Booker Shon, Cheng Alan C, D Amico Derin, D Angelo Noel, Harmange Jean Christophe, Kim Tae Seong, Liu Longbin, Norman Mark H, Siegmund Aaron C, Stec Markian, Xi Ning, Yang Kevin: Nitrogen-containing heterocyclyl ketones and methods of use. Amgen, Albrecht Brian K, Bellon Steven, Booker Shon, Cheng Alan C, D Amico Derin, D Angelo Noel, Harmange Jean Christophe, Kim Tae Seong, Liu Longbin, Norman Mark H, Siegmund Aaron C, Stec Markian, Xi Ning, Yang Kevin, HERMENAU Ronald S, August 28, 2008: WO/2008/103277 (74 worldwide citation)

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and ...


3

4

5
Dipietro Lucian V, Harmange Jean Christophe, Askew Jr Benny C, Elbaum Daniel, Germain Julie, Habgood Gregory J, Kim Joseph L, Patel Vinod F, Potashman Michele, Van Der, Plas Simon: Fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors. Amgen, HERMENAU Ronald S, October 7, 2004: WO/2004/085425 (51 worldwide citation)

The invention relates to compounds of the formulae (I) to (III) wherein the substituents are as defined in the specification. These compounds have kinase inhibitory activity, such as VEGFR/KDR inhibitory activity. Accordingly, the compounds of the formulae (I) to (III) would be useful in the prevent ...


6

7

8
Bellon Steven, Booker Shon, D Angelo Noel, Fellows Ingrid M, Harmange Jean Christophe, Kim Tae Seong, Lee Matthew, Liu Longbin, Norman Mark H: Substituted heterocycles and methods of use. Amgen, Bellon Steven, Booker Shon, D Angelo Noel, Fellows Ingrid M, Harmange Jean Christophe, Kim Tae Seong, Lee Matthew, Liu Longbin, Norman Mark H, HERMENAU Ronald S, July 3, 2008: WO/2008/079291 (32 worldwide citation)

Selected compounds are effective for prophylaxis and treatment of diseases, such as c-met mediated diseases and/or HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxi ...


9
ALBRECHT Brian K, HARMANGE Jean christophe, CÔTÉ Alexandre, TAYLOR Alexandre M: INHIBITEURS À BROMODOMAINE ET LEURS UTILISATIONS, BROMODOMAIN INHIBITORS AND USES THEREOF. CONSTELLATION PHARMACEUTICALS, ALBRECHT Brian K, HARMANGE Jean christophe, CÔTÉ Alexandre, TAYLOR Alexandre M, HSI Jeffrey D, December 20, 2012: WO/2012/174487 (32 worldwide citation)

The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.


10
Harmange Jean Christophe, Booker Shon, Bauer David, Kim Tae Seong, Cheng Yuan, Xu Shimin, Xi Ning, Kim Joseph L, Tasker Andrew: Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer. Amgen, HERMENAU Ronald S, August 11, 2005: WO/2005/073224 (28 worldwide citation)

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and ...